Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

IOL Chemicals & Pharmaceuticals Ltd

₹ 74.6-1.34%
16 Jan – close price
🔗iolcp.com•BSE: 524164•NSE: IOLCP
Market Cap₹ 2,189 Cr.
Current Price₹ 74.6
High / Low₹ 127
Stock P/E18.8
Book Value₹ 59.7
Dividend Yield1.07 %
ROCE8.86 %
ROE6.13 %
Face Value₹ 2.00
Sales₹ 2,170 Cr.
OPM10.6 %
Mar Cap₹ 2,189 Cr.

ABOUT

IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1]It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.[2]

KEY POINTS

Business Segments

Also present in buckets:
Aggressive Growth TriggersExcellent ResultsRevenue GuidanceAsset Base ExpansionCapacity Expansion And ProductsJv Partnerships AcquisitionsRevenue Guidance Vs Actuals

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1668.9034.69400460.330.963124.952.5614478.318.9320.2154964.0130.1211543.963117.955.1512.970.07
2.Divi's Lab.6236.0066.61165513.660.48689.0035.102715.0016.1220.4410029.0032.372485.00689.0010.7413.530.01
3.Torrent Pharma.4018.2062.75135955.090.80591.0032.493302.0014.3027.0512248.0032.602166.53600.1716.1013.260.33
4.Cipla1397.5020.75112878.160.931353.373.737589.447.6422.7228349.5725.405441.141351.173.4314.720.01
5.Lupin2177.9023.0199527.000.551484.8373.347047.5124.2321.3024750.6927.254324.631477.925.0712.410.32
6.Dr Reddy's Labs1175.5017.0098114.930.681336.807.288828.309.8322.6934310.0024.645772.201347.102.7212.950.16
7.Mankind Pharma2175.4051.3789821.630.05520.18-22.003697.1620.7715.9813545.6724.121748.55511.515.878.890.55
8.IOL Chemicals74.5818.852189.411.0730.0056.66567.537.958.862170.3010.55116.1330.001.254.370.09
–Median: 149 Co.392.630.01767.160.1213.9610.46161.7610.5814.89603.8515.9345.2614.123.138.560.22

Quarterly Results

Standalone figures in ₹ crores

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales
541523587563545520504502526523528552568
Expenses
510480491490481476454452484476465490510
Operating Profit
32439673644450514247636257
Other Income
5797788764577
Profit before tax
22338862513238392628454641
Tax %
28%27%25%25%26%28%25%24%26%26%30%25%26%
Net Profit
16246546382328301921323430
EPS in Rs
0.530.822.221.571.290.790.961.010.650.701.081.161.02

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
5643855807119831,6851,8941,9672,1842,2172,1332,0792,170
Expenses
4683735296088631,2761,3211,3751,9271,9901,9011,8771,941
Operating Profit
961151102120410574592257227232202229
Other Income
111161016241725302223
Interest
605961686451216816161516
Depreciation
32293030303236394346637277
Profit before tax
5-75-39631336533571223189183138159
Net Profit
3-67-40528237361445166140135101116
EPS in Rs
0.23-2.80-1.420.170.998.3212.7015.155.644.774.613.443.96
Dividend Payout %
0%0%0%0%0%0%5%8%14%17%22%23%–

Compounded Sales Growth

10 Years:18%
5 Years:2%
3 Years:-2%
TTM:6%

Compounded Profit Growth

10 Years:13%
5 Years:-22%
3 Years:-17%
TTM:16%

Stock Price CAGR

10 Years:19%
5 Years:-12%
3 Years:3%
1 Year:-5%

Return on Equity

10 Years:18%
5 Years:14%
3 Years:8%
Last Year:6%

Balance Sheet

Standalone figures in ₹ crores

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
29485656565757595959595959
Reserves
1601601291321604177571,2021,3321,4481,5531,6291,692
Borrowings
377400453447422284593448033117159
Other Liabilities
17594135182214184297347526434600577503
Total Liabilities
7417027728178529421,1701,6101,9602,0212,2442,3822,413
Fixed Assets
4114034003744064124695125617519331,1701,142
Gross Block
569.47594.29619.96403.77465.53503.91596.66676.81761.99994.711,235.581,543.74–
Accumulated Depreciation
158.86191.47220.4729.8959.8992.19127.62164.45201.35243.40302.89373.40–
CWIP
3344217271948105901012264
Investments
00000001220212121
Other Assets
2972953694224395036821,0481,2921,1591,1901,1681,185
Total Assets
7417027728178529421,1701,6101,9602,0212,2442,3822,413

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
78-47188312027347138091123290179
Cash from Investing Activity
-12-5-27-23-50-63-184-317-121-119-191-154
Cash from Financing Activity
-66509-60-70-197-272-58-2-4-9246
Net Cash Flow
1-2-01-113154-31-0770

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
323155585443525679838190
Inventory Days
190279201201109666498957711195
Days Payable
11992102115834262799574123112
Cash Conversion Cycle
1032181541448067557479866973
Working Capital Days
-55939362343466671727158
ROCE %
11%-3%4%12%15%56%68%54%18%14%12%9%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters
43.69%48.19%48.19%48.19%48.19%48.19%48.19%48.19%52.62%52.62%52.62%52.62%52.62%
FIIs
2.37%2.43%3.54%2.33%2.18%1.40%1.39%1.63%1.49%1.47%2.59%2.25%2.08%
DIIs
0.16%0.23%0.25%0.35%0.36%0.29%0.09%0.07%0.08%0.07%0.02%0.05%0.03%
Public
53.78%49.15%48.02%49.12%49.27%50.11%50.34%50.11%45.81%45.84%44.76%45.10%45.27%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

IOL Chemicals Announces Special Window for Physical Share Dematerialisation

13th April 2026, 8:42 pm

Safety Controls & Devices IPO Allotment Complete; Trading Set to Begin April 13

11th April 2026, 3:36 pm

IOL Chemicals Joins 'Saksham Niveshak' Campaign for Shareholder Dividends & KYC

9th April 2026, 8:28 pm

IOL Chemicals Files SEBI Reg 74(5) Certificate for Quarter Ending March 2026

4th April 2026, 6:55 pm

IOL Chemicals Subsidiary Struck Off; No Material Impact on Operations

1st April 2026, 10:01 pm

Published by Other Websites

External media mentions & references

Indian Market Recovers Midday: Oil Refiners, PSU Banks Surge as Crude Cools

20th March 2026, 2:54 pm

Iran War Disrupts Pharma: IOL Chemicals Faces Propylene Shortage

10th March 2026, 1:52 pm

Indian Companies Land Infra Deals, Face Tax Demands, Boost Green Energy

9th March 2026, 7:41 am

Schaeffler Profit Soars; Aditya Infotech Stake Sale Looms: Stocks in Focus

25th February 2026, 8:15 am

Cochin Shipyard, RIL JV Lead Stocks in Focus as Major Deals Emerge

17th February 2026, 7:33 am

News Articles

Editorial & research coverage

Corporate Action Surge: 50+ Firms Eye Shareholder Payouts Amid Market Wobble
Corporate Action Surge: 50+ Firms Eye Shareholder Payouts Amid Market Wobble

13th February 2026, 1:31 pm

European Approval Boost! IOL Chemicals Poised for Global Expansion with Key API Certification
European Approval Boost! IOL Chemicals Poised for Global Expansion with Key API Certification

5th December 2025, 5:20 pm

Uncover These 3 Breakout Stocks That Just Surged: Market Rally Ignites!
Uncover These 3 Breakout Stocks That Just Surged: Market Rally Ignites!

12th November 2025, 5:44 pm

IOL Chemicals PAT Flat Despite Revenue Growth; Declares Interim Dividend
IOL Chemicals PAT Flat Despite Revenue Growth; Declares Interim Dividend

Documents

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window

29 Dec - Trading window closed from 1 Jan 2026 until 48 hours after Q3/9M results for 31 Dec 2025.

EDQM Issued CEP Certificate For 'MINOXIDIL'

5 Dec 2025 - EDQM granted CEP for Minoxidil API on 4 December 2025.

Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from bse)

Financial Year 2012

(from bse)

Financial Year 2011

(from bse)

Credit Ratings

Rating update

4 Jul 2025 from care

Rating update

5 Nov 2024 from care

Rating update

28 Jun 2024 from care

Rating update

30 Jun 2023 from care

Rating update

4 Jul 2022 from care

Rating update

6 Jul 2021 from care

Concalls

Nov 2025

TranscriptPPT

Aug 2025

TranscriptPPT

May 2025

TranscriptPPTRecording

Feb 2025

TranscriptPPT

Nov 2024

TranscriptPPT

Aug 2024

TranscriptPPTRecording

May 2024

TranscriptPPT

Feb 2024

TranscriptPPT

Nov 2023

TranscriptPPTRecording

Aug 2023

TranscriptPPT

Jun 2023

TranscriptPPT

May 2023

PPT

Feb 2023

TranscriptPPT

Nov 2022

TranscriptPPT

Aug 2022

TranscriptPPT

Jun 2022

TranscriptPPT

Feb 2022

TranscriptPPT

Nov 2021

TranscriptPPT

Aug 2021

TranscriptPPT

Jun 2021

TranscriptPPT

Mar 2021

TranscriptPPT

Dec 2020

TranscriptPPT

Nov 2020

PPT

Stock Analysis

Description

  1. IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and a significant player in the specialty chemicals space, serving domestic and export markets. It is globally the largest producer of Ibuprofen.

Key Growth Triggers

  1. Obtaining EDQM Certificate of Suitability for Pantoprazole Sodium Sesquihydrate, Sitagliptin Phosphate Monohydrate, and Minoxidil, enabling significant European market access and export growth.
  2. Incorporation of IOL Pharmaxis UK Limited to enhance international operations and global market reach.
  3. Strong Q2 FY26 and H1 FY26 financial results showing revenue growth (7.95% YoY for Q2), substantial PAT surge (56.66% YoY for Q2), and improved EBITDA margins (11.1% for Q2).
  4. Strategic focus on diversifying API portfolio beyond Ibuprofen and expanding into regulated markets.

Order Book

Currently no data available for Order Book.

Key Red Flags

  1. Poor sales growth of 1.88% over the last five years.
  2. Low return on equity of 8.09% over the last three years.

Key Dates To Watch

  1. The current report relates to the quarter ended December 31, 2025, with the filing occurring on January 8, 2026.
  2. Related news from the 'old short description' covers events from August 2025 to November 2025, including analyst calls, AGMs, and shareholder engagement campaigns, all of which are historical in the context of the current filing.

Corporate Announcements

13th Apr 26
Impact Rating: -
No description available.
11th Apr 26
Impact Rating: 7
Safety Controls & Devices IPO allotment finalized with 15.84 lakh shares at ₹80 for anchor investors. The company expects to begin trading on April 13, 2026, after receiving BSE approval, marking its public debut.
9th Apr 26
Impact Rating: 7
IOL Chemicals and Pharmaceuticals Limited has joined the 'Saksham Niveshak' initiative to facilitate shareholders in claiming their unpaid dividends and updating KYC details. The campaign runs from April 1, 2026, to July 9, 2026.
4th Apr 26
Impact Rating: 5
IOL Chemicals and Pharmaceuticals Limited filed a certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The filing confirms proper processing of physical share certificates for dematerialization.
1st Apr 26
Impact Rating: 6
IOL Chemicals and Pharmaceuticals has received approval to strike off its wholly owned subsidiary, IOL Life Sciences Limited. The company confirmed this administrative step will not materially impact its financials or day-to-day operations.